Print

VRC 015 (08-I-0171)

A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), Vaccine Research Center (VRC) June 01, 2008
VRC-HIVADV014-00-VP Ad5 Gag-Pol Env A/B/C
VRC-HIVADV014-00-VP Viral Vector - Adeno
USA 31
NCT00709605
http://www.clinicaltrials.gov/ct2/show/NCT00709605?term=vrc015&rank=1